Safety of tumor necrosis factor inhibitor use in patients with concomitant malignancy
Hiep Phan, Rick A. Weideman, Daisha J. Cipher, Linda A. Feagins
Intest Res. 2020;18(3):282-288.   Published online 2020 Apr 7     DOI:
Citations to this article as recorded by Crossref logo
Impact of rheumatoid arthritis and biologic and targeted synthetic disease modifying antirheumatic agents on cancer risk and recurrence
Namrata Singh, Christopher I. Li
Current Opinion in Rheumatology.2021; 33(3): 292.     CrossRef
Can Anti-Tumor Necrosis Factor Agents Be Discontinued in Patients with Inflammatory Bowel Disease?
Jihye Park, Jae Hee Cheon
Gut and Liver.2021; 15(5): 641.     CrossRef